TNF and inflammatory bowel disease: In line with these findings, a Korean study of 110 IBD patients treated with CT-P13 (CD, n = 59 and UC, n = 51) reported that clinical remission rates of 77.3% and 47.8% were achieved in TNF-antagonist-naive CD and UC patients, respectively, after 30 weeks of treatment.[15] Several reports from other observational studies in countries including South Korea, Hungary, Poland and Norway now also support the use of CT-P13 in IBD patients.[16–22]